Sugi Predict

Sugi Predict / Compounds / SCHEMBL3268768

SCHEMBL3268768

SCHEMBL3268768

Oc1ccnc2ccc(Cl)cc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR4A2 P43354 3/20 0.61
▸ SOS2 Q07890 1/20 0.47
▸ MAPKAPK2 P49137 3/20 0.47
▸ TLR8 Q9NR97 1/20 0.45
▸ PARP1 P09874 1/20 0.44
▸ CCNC P24863 1/20 0.44
▸ CDK8 P49336 1/20 0.44
▸ GAA P10253 3/20 0.44
▸ MAPT P10636 3/20 0.44
▸ ATM Q13315 1/20 0.44
▸ KMT2A Q03164 3/20 0.43
▸ TDP1 Q9NUW8 3/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ CA9 Q16790 1/20 0.43
▸ MCL1 Q07820 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ GAK O14976 1/20 0.42
▸ RIPK2 O43353 1/20 0.42
▸ COQ8A Q8NI60 1/20 0.42
▸ NLK Q9UBE8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29945144 1.00 NR4A2 (0.61) NR4A2SOS2MAPKAPK2TLR8PARP1
SCHEMBL409748 0.84 NR4A2 (0.61) NR4A2SOS2TLR8GAAMAPT
SCHEMBL30772330 0.84 NR4A2 (0.61) NR4A2SOS2TLR8GAAMAPT
Hydrochloric Acid SCHEMBL1611213 0.82 NR4A2 (0.59) NR4A2SOS2TLR8GAAMAPT
SCHEMBL1888577 0.79 NR4A2 (0.66) NR4A2SOS2PARP1CCNCCDK8
SCHEMBL30819181 0.79 PARP1 (0.47) NR4A2MAPKAPK2TLR8PARP1GAA
SCHEMBL1332713 0.79 PARP1 (0.47) NR4A2MAPKAPK2TLR8PARP1GAA
SCHEMBL30051309 0.79 NR4A2 (0.66) NR4A2SOS2PARP1CCNCCDK8
SCHEMBL25240188 0.78 KMT5B (0.46) NR4A2SOS2TLR8GAAMAPT
SCHEMBL29951934 0.77 ENPP2 (0.43) NR4A2MAPTKMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114534694-B Hydroxyquinoline filler and preparation method and application thereof 万华化学集团股份有限公司 2024-08-16 — — CN claimed
WO-2022193350-A1 NEW PROCESS FOR SYNTHESIZING 4-HYDROXY-6-CHLOROQUINOLINE 德州学院 2022-09-22 — — WO claimed
CN-114534694-A Hydroxyquinoline filler and preparation method and application thereof 万华化学集团股份有限公司 2022-05-27 — — CN claimed
CN-112961106-A Novel synthesis process of 4-hydroxy-6-chloroquinoline 德州学院 2021-06-15 — — CN claimed
US-12486234-B2 PAPD5 inhibitors and methods of use thereof CHILDREN'S MEDICAL CENTER CORPORATION (US) 2025-12-02 — — US disclosed
WO-2025090465-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-05-01 — — WO disclosed
EP-4055014-B1 PYRROLIDINE AND PIPERIDINE COMPOUNDS YUHAN CORP (KR) 2025-04-30 — — EP disclosed
US-12281080-B2 Quinoline-based compounds and methods of inhibiting CDK8/19 UNIVERSITY OF SOUTH CAROLINA (US) 2025-04-22 — — US disclosed
CN-119798159-A PAPD5 inhibitors and methods of use thereof 儿童医学中心公司 2025-04-11 — — CN disclosed
EP-4514791-A1 SUBSTITUTED 6- (PYRIMIDIN-4-YL) QUINOLINE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS BeiGene, Ltd. (KY) 2025-03-05 — — EP disclosed
US-20250026769-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2025-01-23 — — US disclosed
CN-119095840-A Substituted 6- (pyrimidin-4-yl) quinoline compounds as cyclin dependent kinase inhibitors 百济神州有限公司 2024-12-06 — — CN disclosed
CN-85106626-A The preparation of 4-amino-2-phenyl-quinoline — 1987-03-25 — — CN disclosed
EP-0168812-A1 4-Amino-2-phenyl quinolines, methods and intermediates for their preparation and medicaments containing them F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1986-01-22 — — EP disclosed
EP-0168309-A1 Isoxazoloquinolinone derivatives, process and intermediates for their preparation, use as medicaments and compositions containing them ROUSSEL-UCLAF (FR) 1986-01-15 — — EP disclosed
US-4560692-A ANTICONVULSANTS OR ANXIOLYTIC AGENTS HOFFMANN-LA ROCHE INC. (US) 1985-12-24 — — US disclosed
US-4447435-A HYPOTENSIVE AGENTS THE BOOTS COMPANY PLC (GB) 1984-05-08 — — US disclosed
US-4442109-A 3-Methylthiomethyl-and 3-methylsulfinylmethyl-4-quinolinones useful for treating hypertension THE BOOTS COMPANY LIMITED (GB) 1984-04-10 — — US disclosed
US-3931192-A Process for piperidine intermediates for quinine, quinidine and analogs thereof HOFFMANN-LA ROCHE INC. (US) 1976-01-06 — — US disclosed
US-3931193-A ANTIMALARIA, ANTIARRHYTHMIA INTERMEDIATES HOFFMANN-LA ROCHE INC. (US) 1976-01-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12486234-B2 PAPD5 inhibitors and methods of use thereof POT1, PARP15, TERT NR4A2 3545/4885SOS2 4446/4885MAPKAPK2 1802/4885
US-20250026769-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF POT1, PARP15, TERT NR4A2 3583/4885SOS2 4372/4885MAPKAPK2 1901/4885
US-12281080-B2 Quinoline-based compounds and methods of inhibiting CDK8/19 CDK8, CDK9, CDK19 NR4A2 1278/4885SOS2 2848/4885MAPKAPK2 246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.